Ivabradine Hydrochloride: Antianginal HCN (If Current) Blocker

Drugs of the Future

Volumn 28, Issue 7, 2003, Pages 652-658

  Sorbera, L A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; AREA UNDER THE CURVE; BRADYCARDIA; CLINICAL TRIAL; DIASTOLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEART DEPOLARIZATION; HEART MUSCLE ISCHEMIA; HEART RATE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERPOLARIZATION; HYPOTENSION; INOTROPISM; LONG QT SYNDROME; MALE; MEMBRANE CHANNEL; NONHUMAN; RAT; REVIEW; SIDE EFFECT; SINUS NODE;

EID: 0142073853     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.07.742713     Document Type: Review

References (53)

1. Peglion, J.-L., Vian, J., Vilaine, J.-P., Villeneuve, N., Janiak, P., Bidouard, J.-P. (ADIR et Cie.). Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substd. 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases. EP 0534859, FR 2681862, JP 1993213890, US 5296482.
2. Prous Science Drug R&D Backgrounders: Angina pectoris (online publication). Updated July 9, 2003.
3. Frishman, W.H. Multifactorial actions of β-adrenergic blocking drugs in ischemic heart disease: Current concepts. Circulation 1983, 67(Suppl. I): 11-8.
4. Frishman, W.H., Sonnenblick, E.H. Calcium-channel blockers In: The Heart, 8th ed., R.C. Schlant and R. Alexander(Eds.), McGraw Hill, New York, 1994, 1291-308.
5. Opie, L.H. Pharmacology of acute effort angina. Cardiovasc Drugs Ther 1989, 3: 257-70.
6. Kern, M.J., Deligonul, U., Labovitz, A. Influence of drug therapy on the ischemic response to acute coronary occlusion in man: Supply-side economics. Am Heart J 1989, 118: 361-80.
7. Irisawa, H., Brown, H.F., Giles, W. Cardiac pacemaking in the sinoatrial node. Physiol Rev 1993, 73: 197-22.
8. f in rabbit sinoatrial node cells by zatebradine (UL-FS 49). On the mode of action of sinus node inhibitors. Circulation 1993, 88: 2389-401.
9. f) in guinea-pig dissociated sinoatrial node cells. Br J Pharmacol 1993, 110: 343-9.
10. Thollon, C., Cambarrat, C., Vian, J., Prost, J.F., Peglion, J.L., Vilaine, J.P. Electrophysiological effects of S 16257, a novel sinoatrial node modulator, on rabbit and guinea-pig cardiac preparations: Comparison with UL-FS 49. Br J Pharmacol 1994, 112: 37-42.
11. l) in sino-atrial node myocytes. Pflüg Arch Eur J Physiol 1994, 427: 64-70.
12. h) blocker ZD 7288 in hippocampal CA1 neurons. Pflüg Arch Eur J Physiol 1997, 435: 99-106.
13. Shin, K.S., Rothberg, B.S., Yellen, G. Blocker state dependence and trapping in hyperpolarization-activated cation channels: Evidence for an intracellular activation gate. J Gen Physiol 2001, 117: 91-101.
14. Thollon, C., Bidouard, J.-P., Cambarrat, C., Lesage, L., Reure, H., Delescluse, I., Vian, J., Peglion, J.-L., Vilaine, J.-P. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997, 339: 43-51.
15. Pérez, O., Gay, P., Franqueza, L., Carrón, R., Valenzuela, C., Delpón, E., Tamargo, J. Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. Br J Pharmacol 1995, 115: 787-94.
16. Bel, A., Perrault, L.P., Faris, B., Mouas, C., Vilaine, J.-P., Menasché P. Inhibition of the pacemaker current: A bradycardic therapy for off-pump coronary operations. Ann Thorac Surg 1998, 66: 148-52.
17. Bois, P., Bescond, J., Renaudon, B., Lenfant, J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996, 118: 1051-7.
18. f channels by ivabradine. J Gen Physiol 2002, 120: 1-13.
19. Zong, X., Mahlberg-Gaudin, F., Hofmann, F., Biel, M. Inhibition of human cardiac pacemaker channels HCN2 and HCN4 by ivabradine (S 16257-2). Naunyn-Schmied Arch Pharmacol 2002, 365(Suppl. 1): Abst 374.
20. Delpón, E., Valenzuela, C., Pérez, O., Franqueza, L., Gay, P., Snyders, D.J., Tamargo, J. Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. Br J Pharmacol 1996, 117: 1293-301.
21. Gardiner, S.M., Kemp, P.A., March, J.E., Bennett, T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995, 115: 579-86.
22. Mangin, L., Swynghedauw, B., Benis, A., Thibault, N., Lerebours, G., Carré, F. Relationships between heart rate and heart rate variability: Study in conscious rats. J Cardiovasc Pharmacol 1998, 32: 601-7.
23. f current inhibitor ivabradine improves cardiac function and structure in rats with heart failure. Eur Heart J 2002, 23(Suppl.): Abst 1969.
24. Simon, L., Ghaleh, B., Puybasset, L., Giudicelli, J.-F., Berdeaux, A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995, 275: 659-66.
25. Monnet, X., Ghaleh, B., Colin, P., Parent de Curzon, O., Giudicelli, J.-F., Berdeaux, A. Effects of heart rate reduction with ivabradine on exercise induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001, 299: 1133-9.
26. Colin, P., Ghaleh, B., Monnet, X., Su, J., Hittinger, L., Giudicelli J.-F., Berdeaux, A. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol - Heart Circ Physiol 2003, 284: H676-82.
27. Colin, P., Ghaleh, B., Hittinger, L., Monnet, X., Slama, M., Giudicelli, J.-F., Berdeaux, A. Differential effects of heart rate reduction and β blockade on left ventricular relaxation during exercise. Am J Physiol - Heart Circ Physiol 2002, 282: H672-9.
28. Klippert, P., Jeanniot, J.-P., Polve, S., Lefevre, C., Merdjan, H. Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high performance liquid chromatographic method with fluorescence detection. J Chromatogr B - Biomed Sci Appl 1998, 719: 125-33.
29. Francois-Bouchard, M., Simonin, G., Bossant, M.-J., Boursier-Neyret, C. Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B - Biomed Sci Appl 2000, 745: 261-9.
30. Duffull, S.B., Aarons, L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 2000, 10: 275-84.
31. Duffull, S.B., Chabaud, S., Nony, P., Laveille, C., Girard, P., Aarons, L. A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 2000, 10: 285-94.
32. Evans, N.D., Godfrey, K.R., Chapman, M.J., Chappell, M.J., Aarons, L., Duffull, S.B. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Pharmacodyn 2001, 28: 93-105.
33. Duffull, S.B., Mentré, F., Aarons, L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001, 18: 83-9.
34. Ragueneau, I., Laveille, C., Jochemsen, R., Resplandy, G., Funck Brentano, C., Jaillon, P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998, 64: 192-203.
35. Carré, F., Beillot, J., Dassonville, J., Alberini, H., Denolle, T., Weber, C., Lerebours, G. Effects of a sinus node inhibitor, S-16257 on the maximal aerobic exercise parameters. Pflug Arch Eur J Physiol 1995, 430(4, Suppl.): Abst 416.
36. Nony, P., Girard, P., Delair, S., Fayn, J., Forlini, M.C., Arnaud, P., Rubel, P., Violet, I., Lerebours, G., Boissel, J.P. Electrophysiologic effects of S 16257-2, a sino-atrial modulator agent, in healthy subjects: A surface ECG study. Naunyn-Schmied Arch Pharmacol 1998, 358(1, Suppl. 2): Abst P 36.44.
37. Nony, P., Delair, S., Girard, P., Fayn, J., Forlini, M.C., Arnaud, P., Rubel, P., Resplandy, G., Lerebours, G., Boissel, J.P. Dose-effect relationship after administration of 10, 20 and 30 mg of S16257-2, a sino-atrial modulator agent, in healthy subjects. Naunyn-Schmied Arch Pharmacol 1998, 358(1, Suppl. 2): Abst P 46.16.
38. Eckl, K.M., Thomsen, T., Möller, M., Violet, I., Dubois, F. The bradycardic effect of the sinoatrial modulator S 16257. Eur Heart J 1997, 18(Suppl): Abst P1047.
39. Chabaud, S., Girard, P., Nony, P., Boissel, J.P. Clinical trial simulation using therapeutic effect modeling: Application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002, 29: 339-63.
40. Borer, J.S., Fox, K., Jaillon, P., Lerebours, G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107: 817-23.
41. Research and Development. Servier Web Site May 29, 2003.
42. f current inhibitor ivabradine improves cardiac function and structure in rats with congestive heart failure. Circulation 2001, 104(17, Suppl. 2): Abst 798.
43. Simon, L., Ghaleh, B., Puybasset, L., Giudicelli, J.F., Berdeaux, A. Coronary and systemic hemodynamic effects of the new sinoatrial inhibitor, S16257, in resting and exercised conscious dogs. Pharmacol Res 1995, 31(Suppl.): 28.
44. Monnet, X., Ghaleh, B., Colin, P., Parent de Curzon, O., Giudicelli, J.F., Berdeaux, A., Bizé, A. Heart rate reduction by ivabradine exerts both preventive and curative effects on exercise-induced myocardial stunning in dogs. Eur Heart J 2001, 22(Suppl.): Abst P3697.
45. Monnet, X., Colin, P., Ghaleh, B., Bizé, A., Giudicelli, J.F., Berdeaux, A. Heart rate reduction and negative inotropism exert contrasting cardioprotective effects during exercise-induced ischaemia and stunning in dogs. Eur Heart J 2002, 23(Suppl.): Abst P1186.
46. Peglion, J.L., Vian, J., Thollon, C., Janiak, P., Vilaine, J.P. S 16257, a novel sino atrial node modulator: Potent bradycardic activity with improved specificity. Can J Physiol Pharmacol 1994, 72(Suppl. 1): Abst P1.4.4.
47. Péglion, J.L., Vian, J., Thollon, C., Janiak, P., Vilaine, J.P. Characterization of S 16257, a novel and highly specific sinoatrial node modulator, displaying potent bradycardic activity. 13th Int Symp Med Chem (Sept 19-23, Paris) 1994, Abst P61.
48. Godin-Ribout, D., Ribout, C., Arvieux, C.C., Lucien, A., Demenge, P. In vivo electrophysiological effects, of S-16257, a specific bradycardic agent, in the dog. J Mol Cell Cardiol 1998, 30: Abst 4.
49. Mangin, L., Swynghedauw, B., Thibault, N., Carre, F. Effects of the novel bradycardic agent S-16257, on heart rate variability in conscious rats. J Mol Cell Cardiol 1997, 29(5): A116.
50. Ragueneau, I., Laveille, C., Jochemsen, R., Weber, C., Funck-Brentano, C., Jaillon, P. Pharmacokinetic-pharmacodynamic modelling of the effects of S-16257, a direct sinus node modulator, on heart rate in healthy volunteers. Eur J Clin Pharmacol 1997, 52(Suppl.): Abst 334.
51. Colin, P., Ghaleh, B., Hittinger, L., Monnet, X., Slama, M.S., Giudicelli, J.F., Berdeaux, A., Bizé, A., Caillaud, D. Differential effects of ivabradine, a selective bradycardic agent and the β-blocker, atenolol, on left ventricular relaxation in exercising dogs. Eur Heart J 2001, 22(Suppl.): Abst 2749.
52. Colin, P., Ghaleh, B., Hittinger, L., Monnet, X., Slama, M., Giudicelli, J.-F., Berdeaux, A. Differential effects of the selective bradycardic agent, ivabradine, and atenolol on left ventricular relaxation in exercising dogs. Circulation 2001, 104(17, Suppl. 2): Abst 2700.
53. f inhibitor, in stable angina: A randomized, double-blinded, placebo-controlled trial. Circulation 2002, 106(19, Suppl. 2): Abst 3132.